Supportive Care Articles

FDA Expands Indication for Scalp Cooling System to Include All Solid Tumors
The FDA has expanded the indication for the Orbis Paxman Hair Loss Cooling System to prevent chemotherapy-related alopecia in patients with solid tumors.
Cognitive Behavior Therapy, Acupuncture Improve Insomnia Symptoms in Cancer Survivors
Both cognitive behavior therapy for insomnia (CBT-I) and acupuncture produced clinically meaningful improvements in insomnia severity scores for cancer survivors, but data from the randomized CHOICE clinical trial showed that CBT-I was more effective overall for reducing the severity of insomnia.
FDA Approves Fostamatinib for Chronic ITP
The FDA has approved the SYK inhibitor fostamatinib as a second-line treatment for patients with chronic immune thrombocytopenia following insufficient response to a previous therapy.
Homing in on the Real Needs of Cancer Patients
Hyman B Muss, MD, a 2017 Giants of Cancer Care® award winner is a pioneer in the treatment of older patients with cancer.
Preventing Clinical Lymphedema With Bioimpedance Spectroscopy
Employing preclinical detection using bioimpedance spectroscopy, breast centers are reporting progression to clinical lymphedema in less than 10% of patients at high risk of developing the condition.
Effective Management of CINV Improves Response to Treatment
The goal of selecting optimal antiemetic therapy continues to be a moving target with the emergence of newer agents and patient-related risk factors, as well as the rapid evolution of guidelines for the management of chemotherapy-induced nausea and vomiting.
Despite the widespread availability of antiemetic regimens, between 30% and 50% of patients receiving chemotherapy experience treatment-related nausea and/or vomiting.
The FDA has approved intravenous rolapitant for use in combination with other antiemetic agents to treat delayed chemotherapy-induced nausea and vomiting in adults.
FDA Issues Complete Response Letter for Pegfilgrastim Biosimilar
Biocon has announced that the FDA has issued a complete response letter for Mylan’s biologics License Application for MYL-1401H, a proposed biosimilar for Amgen’s pegfilgrastim (Neulasta).
FDA Approves Ibrutinib for GVHD
The FDA has approved ibrutinib for the treatment of adult patients with chronic graft versus host disease following the failure of 1 or more lines of systemic therapy. The BTK inhibitor is now the first FDA-approved therapy for the treatment of cGVHD.
Publication Bottom Border
Border Publication